Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of LNA043 in Japanese participants with knee osteoarthritis
jRCT2080225367Phase 1Completed
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LNA043 in knee osteoarthritis (OA) (4 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of single intra-articular doses of LNA043 and Pharmacokinetics of LNA043. Started Aug 2020; status: completed.
02
Drugs
LNA043
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2080225367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225367.